Unlocking the potential of
genomic medicine


Aevi Genomic Medicine is focused on translating genetic discoveries into novel therapies to improve the lives of children and adults with pediatric onset life altering diseases.  More>>

There are no items to display.

Stock Quote

Recent News

More >>
Date Title and Summary
Toggle Summary03/05/2014
WAYNE, Pa. and MISGAV, Israel , March 5, 2014 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE:MDGN) (AIM:MEDU) (AIM:MEDG), the developer of BioPump™, a novel platform technology for the sustained production and delivery of therapeutic proteins in patients using ex-vivo gene therapy and their own tissue
Toggle Summary10/10/2016
PHILADELPHIA, PA -- (Marketwired) -- 10/10/16 -- Medgenics, Inc. (NYSE MKT: MDGN) (the "Company") announced today that it has been approved for listing on the NASDAQ Global Market , continuing to trade under the symbol "MDGN." Trading on the NASDAQ Global Market is expected to commence on October
Toggle Summary12/15/2016
PHILADELPHIA , Dec. 15, 2016 /PRNewswire/ --  Medgenics, Inc. (NASDAQ: MDGN) today announced that the company has changed its name to Aevi Genomic Medicine, Inc.  Aevi Genomic Medicine (pronounced "AHH-vee") is a name inspired by the Old Norse language which means "life story" and reflects the

Recent Presentations

More >>
Date Title

Upcoming Events

More >>
There are currently no events to display.

Receive E-mail Alerts

Sign up to receive e-mail alerts whenever Aevi Genomic Medicine, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Copyright Nasdaq. Minimum 15 minutes delayed.